(WFRF:(Backman Helena)) srt2:(2010-2014)
Sökning: (WFRF:(Backman Helena)) srt2:(2010-2014) > (2011) > Costs of COPD by di...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Jansson, Sven-Arne (författare)
Costs of COPD by disease severity
- Artikel/kapitelEngelska2011
Förlag, utgivningsår, omfång ...
- 2011
- printrdacarrier
Nummerbeteckningar
- LIBRIS-ID:oai:DiVA.org:umu-103805
- https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-103805URI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Background: Chronic obstructive pulmonary disease (COPD) is one of the most common chronic and disabling diseases worldwide, and the societal costs are high.Aim: To estimate the societal costs of COPD in Sweden and to examine the relationship between disease severity and costs.Methods: The study sample was identified in earlier clinical examinations of general population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden) studies. The cohort consisted initially of 993 subjects fulfilling COPD spirometric criteria (GOLD). In 2009-2010, telephone interviews on resource utilization were made to a sample of 244 subjects, stratified by disease severity. Interviews were performed quarterly to minimize the risk of recall bias. A non-parametric Mann-Whitney U-test was used to test cost differences between groups; p-values adjusted by Bonferroni correction. Unit costs from 2010 were applied.Results: A highly significant relationship was found between disease severity and costs. The mean annual total cost per patient in relation to disease severity (GOLD) was: stage I €811; II €2,660; III €7,068; and IV €20,665. Indirect costs were higher than direct costs in all severity stages. For direct costs, main cost drivers were hospitalizations in stage III and IV, and drugs in stage I and II, respectively. The main cost driver in indirect costs was productivity loss due to early retirement, except in stage I where the driver was sick-leave. In comparison with a similar study performed in 1999 a numerical increase in mean annual total costs per patient was observed (ns).Conclusions: The results indicate that the societal costs of COPD in Sweden are substantial, and the costs increase considerably by disease severity.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Backman, Helena (författare)
- Stenling, AnnaAstraZeneca Nordic(Swepub:umu)anabei01 (författare)
- Lindberg, AnneUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)anelig02 (författare)
- Rönmark, EvaUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)evra0004 (författare)
- Lundbäck, Bo (författare)
- AstraZeneca NordicInstitutionen för folkhälsa och klinisk medicin (creator_code:org_t)
Sammanhörande titlar
- Ingår i:European Respiratory Journal38:Suppl 550903-19361399-3003
Internetlänk
Hitta via bibliotek
- European Respiratory Journal (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Jansson, Sven-Ar ...
- Backman, Helena
- Stenling, Anna
- Lindberg, Anne
- Rönmark, Eva
- Lundbäck, Bo
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Lungmedicin och ...
- Artiklar i publikationen
- European Respira ...
- Av lärosätet
- Umeå universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
